Acorda Therapeutics, Inc. (hereinafter the “Offeror” or “Acorda”) and Biotie Therapies Corp. (hereinafter “Biotie” or the “Company”) have announced a voluntary public tender offer (the “Offer”) by Acorda for the issued and outstanding ordinary shares, no nominal value, of the Company (the “Shares”), the outstanding American Depositary Shares, each representing 80 Shares (the “ADSs”), and the outstanding Equity Instruments (as defined below) in Biotie by stock exchange release dated January 19, 2016.
